Tags

Type your tag names separated by a space and hit enter

Adenosine receptors and caffeine in retinopathy of prematurity.
Mol Aspects Med. 2017 06; 55:118-125.MA

Abstract

Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Notably, cellular responses to hypoxia are characterized by robust increases in extracellular adenosine production and the markedly induced adenosine receptors, which provide a novel target for preferential control of pathological angiogenesis without affecting normal vascular development. Here, we review the experimental evidence in support of adenosine receptor-based therapeutic strategy for ROP, including the aberrant adenosine signaling in oxygen-induced retinopathy and the role of three adenosine receptor subtypes (A1R, A2AR, A2BR) in development and treatment of ROP using oxygen-induced retinopathy models. The clinical and initial animal evidence that implicate the therapeutic effect of caffeine (a non-selective adenosine receptor antagonist) in treatment of ROP are highlighted. Lastly, we discussed the translational potential as well therapeutic advantage of adenosine receptor- and caffeine-based therapy for ROR and possibly other proliferative retinopathy.

Links

PMC Free PDF

Authors+Show Affiliations

Chen JF
Molecular Neuropharmacology Laboratory, School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health of China, Wenzhou, Zhejiang, China. Electronic address: chenjf555@gmail.com.
Zhang S
Molecular Neuropharmacology Laboratory, School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China; State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health of China, Wenzhou, Zhejiang, China.
Zhou R
State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health of China, Wenzhou, Zhejiang, China.
Lin Z
Department of Neonatology, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Cai X
Department of Neonatology, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lin J
Department of Neonatology, Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China; Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Huo Y
Vascular Biology Center, Department of Cellular Biology and Anatomy, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, USA; Drug Discovery Center, Key Laboratory of Chemical Genomics, Peking University Shenzhen Graduate School, Shenzhen 518055, China.
Liu X
State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health of China, Wenzhou, Zhejiang, China.

MeSH

AnimalsCaffeineDisease Models, AnimalHumansInfant, NewbornOxygenPurinergic P1 Receptor AntagonistsReceptors, Purinergic P1RetinaRetinal NeovascularizationRetinopathy of Prematurity

Pub Type(s)

Journal Article
Review
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

28088487

Citation

Chen, Jiang-Fan, et al. "Adenosine Receptors and Caffeine in Retinopathy of Prematurity." Molecular Aspects of Medicine, vol. 55, 2017, pp. 118-125.
Chen JF, Zhang S, Zhou R, et al. Adenosine receptors and caffeine in retinopathy of prematurity. Mol Aspects Med. 2017;55:118-125.
Chen, J. F., Zhang, S., Zhou, R., Lin, Z., Cai, X., Lin, J., Huo, Y., & Liu, X. (2017). Adenosine receptors and caffeine in retinopathy of prematurity. Molecular Aspects of Medicine, 55, 118-125. https://doi.org/10.1016/j.mam.2017.01.001
Chen JF, et al. Adenosine Receptors and Caffeine in Retinopathy of Prematurity. Mol Aspects Med. 2017;55:118-125. PubMed PMID: 28088487.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adenosine receptors and caffeine in retinopathy of prematurity. AU - Chen,Jiang-Fan, AU - Zhang,Shuya, AU - Zhou,Rong, AU - Lin,Zhenlang, AU - Cai,Xiaohong, AU - Lin,Jing, AU - Huo,Yuqing, AU - Liu,Xiaoling, Y1 - 2017/01/11/ PY - 2016/10/01/received PY - 2016/12/28/revised PY - 2017/01/10/accepted PY - 2017/1/16/pubmed PY - 2018/3/23/medline PY - 2017/1/16/entrez KW - Adenosine KW - Adenosine (A(1), A(2A), A(2B)) receptors KW - Caffeine KW - Oxygen-induced retinopathy KW - Retinopathy of prematurity SP - 118 EP - 125 JF - Molecular aspects of medicine JO - Mol Aspects Med VL - 55 N2 - Retinopathy of prematurity (ROP) is a major cause of childhood blindness in the world and is caused by oxygen-induced damage to the developing retinal vasculature, resulting in hyperoxia-induced vaso-obliteration and subsequent delayed retinal vascularization and hypoxia-induced pathological neovascularization driven by vascular endothelial growth factor (VEGF) signaling pathway in retina. Current anti-VEGF therapy has shown some effective in a clinical trial, but is associated with the unintended effects on delayed eye growth and retinal vasculature development of preterm infants. Notably, cellular responses to hypoxia are characterized by robust increases in extracellular adenosine production and the markedly induced adenosine receptors, which provide a novel target for preferential control of pathological angiogenesis without affecting normal vascular development. Here, we review the experimental evidence in support of adenosine receptor-based therapeutic strategy for ROP, including the aberrant adenosine signaling in oxygen-induced retinopathy and the role of three adenosine receptor subtypes (A1R, A2AR, A2BR) in development and treatment of ROP using oxygen-induced retinopathy models. The clinical and initial animal evidence that implicate the therapeutic effect of caffeine (a non-selective adenosine receptor antagonist) in treatment of ROP are highlighted. Lastly, we discussed the translational potential as well therapeutic advantage of adenosine receptor- and caffeine-based therapy for ROR and possibly other proliferative retinopathy. SN - 1872-9452 UR - https://www.unboundmedicine.com/medline/citation/28088487/Adenosine_receptors_and_caffeine_in_retinopathy_of_prematurity_ DB - PRIME DP - Unbound Medicine ER -